[ParlTrack]

Herbert REUL, Norbert GLANTE, Maria da Graça CARVALHO, Lena KOLARSKA-BOBIŃSKA, Ioan ENCIU, Adam GIEREK, Silvia-Adriana ȚICĂU

Proposal for a decision
Annex 1 – section 1 – point 4 a (new)

4 a. Spreading Excellence and Widening Participation In order to help close the research and innovation divide in Europe, complementarity and close synergies will be developed with the Structural Funds both upstream (capacity-building in the Member States to better prepare their participation in Horizon 2020) and downstream (exploit and diffuse research and innovation results stemming from Horizon 2020). Where possible, interoperability between the two instruments will be promoted. Cumulative or combined funding will be encouraged. In this context, measures will aim at fully exploiting the potential of Europe's talent pool and thereby optimising the economic and social impact of research and innovation and will be distinct yet complementary with regard to policies and actions of the Cohesion policy Funds. These measures include: (a) Linking emerging institutions, centres of excellence and innovative regions in less developed Member States to leading international counterparts elsewhere in Europe. This will involve twinning of staff exchanges, expert advice and assistance and the development of joint strategies for the development of centres of excellence. This may be supported by the Cohesion policy funds in less developed regions. Building links with innovative clusters and recognising excellence in less developed regions, including through peer reviews and awarding labels of excellence to those institutions that meet international standards, will be considered. (b) Launching a competition for the foundation of internationally competitive research centres in cohesion regions: the candidates for the competition should be teams each comprising an innovative but still less developed region and an internationally recognised centre of excellence elsewhere in Europe. The scientific concepts underlying the newly founded research institutes should be assessed on the principle of excellence; the regions should be required to come up with a viable overall approach for an infrastructure and overall environment amenable to research and innovation, something to be built up with the help of their structural funds; this competition should provide a powerful complement to the efforts of the economically weaker regions to develop a long term smart specialisation strategy. (c) Establishing 'ERA Chairs' to attract outstanding academics to institutions with a clear potential for research excellence, in order to help these institutions fully unlock this potential and thereby create a level playing field for research and innovation in the European Research Area. This will include institutional support for creating a competitive research environment and the framework conditions necessary for attracting, retaining and developing top research talent within these institutions. (d) Conferring a "seal of excellence" on positively evaluated ERC, Marie Sklodowska-Curie or collaborative project proposals that have not been able to achieve funding because of budgetary limitations. National and regional funds might thus be encouraged to contribute to the funding of those projects that meet the criteria of excellence but cannot be funded due to lack of European funds. (e) Conferring a "seal of excellence" to completed projects in order to facilitate funding of the follow up (e.g. pilot scale, demonstration projects or valorisation of research results) by national or regional sources. (f) Attribution of ERC "Return Grants" to researchers currently working outside of Europe and who wish to work in Europe or to researchers already working in Europe who wish to move to a less developed region. (g) Support complementary agreements signed among organisations beneficiaries of the collaborative research projects with other entities and organisations established mainly in countries others than those directly involved in the project with the specific objective of facilitating training opportunities (namely doctoral and post-doctoral positions) (h) Strengthening successful networks aiming at establishing high quality institutional networking in research and innovation. Particular attention will be paid to COST in order to promote activities to identify and connect "pockets of excellence" (high-quality scientific communities and early career investigators) throughout Europe. (i) Developing specific training mechanisms on how to participate in Horizon 2020, taking full advantage of existing networks such as the National Contact Points. (j) Making available doctoral and post- doctoral fellowships, as well as advanced training fellowships for engineers for accessing all international research infrastructures in Europe, including those managed by international scientific organisations. (k) Supporting the development and monitoring of smart specialisation strategies. A policy support facility will be developed and policy learning at regional level will be facilitated through international evaluation by peers and best practice sharing. (l) Setting up an online marketplace where intellectual property can be advertised in order to bring together the owners and users of IPR.

2012/07/04
Committee: ITRE

Peter LIESE, Herbert REUL, Markus PIEPER, Werner LANGEN, Christian EHLER, Daniel CASPARY, Konrad SZYMAŃSKI, Maria da Graça CARVALHO

Proposal for a decision
Annex 1 – section 2 – point 1 – point 1.4 – point 1.4.3 – paragraph 1

The objective is to develop platform technologies (e.g. genomics, meta- genomics, proteomics, molecular tools) triggering leadership and competitive advantage on a wide number of economic sectors. It includes aspects, such as underpinning the development of bio- resources with optimised properties and applications beyond conventional alternatives; enabling exploration, understanding and exploitation in a sustainable manner of terrestrial and marine biodiversity for novel applications; Priority support will be given to new diagnostic methods where a prevention or diagnosis for the patient in question either already exists or is likely to be developed.

2012/07/04
Committee: ITRE

Peter LIESE, Herbert REUL, Markus PIEPER, Werner LANGEN, Christian EHLER, Daniel CASPARY, Konrad SZYMAŃSKI, Maria da Graça CARVALHO

Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.2 – paragraph 1

The development of screening programmes depends on the identification of early biomarkers of risk and of disease onset, and their deployment depends on the testing and validation of screening methods and programmes. Identifying individuals and populations at high-risk of disease will allow personalised, stratified and collective strategies for efficacious and cost effective disease prevention to be developed. In this connection, priority will be given to screening programmes where prevention or therapy for the patient concerned are available or are likely to be developed.

2012/07/05
Committee: ITRE

Peter LIESE, Markus PIEPER, Herbert REUL, Werner LANGEN, Christian EHLER, Daniel CASPARY, Konrad SZYMAŃSKI, Maria da Graça CARVALHO

Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.6 – paragraph 1

An improved understanding of health, disease and disease processes at all ages is needed to develop new and more effective diagnostics. Innovative and existing technologies will be developed with the goal of significantly improving disease outcomes through earlier, more accurate diagnosis and by allowing for more patient-adapted treatment. In this connection, priority will be given to diagnostic methods where prevention or therapeutic measures for the patients concerned are available or are likely to be available in the near future.

2012/07/05
Committee: ITRE

Peter LIESE, Herbert REUL, Markus PIEPER, Werner LANGEN, Christian EHLER, Daniel CASPARY, Konrad SZYMAŃSKI, Maria da Graça CARVALHO

Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.8 – paragraph 1

There is a need to support the improvement of cross-cutting support technologies for drugs, vaccines and other therapeutic approaches, including transplantation, gene and cell therapy, particularly adult stem cell therapy, umbilical cord blood cell and iPS cell therapies; to increase success in the drug and vaccine development process (including alternative methods to replace classical safety and effectiveness testing e.g. the development of new methods); to develop regenerative medicine approaches, including approaches based on stem cells; to develop improved medical and assistive devices and systems; to maintain and enhance our ability to combat communicable, rare, major and chronic diseases and undertake medical interventions that depend on the availability of effective antimicrobial drugs; and to develop comprehensive approaches to treat co-morbidities at all ages and avoid poly-pharmacy. These improvements will facilitate the development of new, more efficient, effective and sustainable treatments for disease and for the management of disability. There is a need to develop ideas in the field of regenerative medicine, particularly based on adult stem cells, umbilical cord blood cells and iPS cells.

2012/07/05
Committee: ITRE

Peter LIESE, Herbert REUL, Markus PIEPER, Werner LANGEN, Christian EHLER, Daniel CASPARY, Konrad SZYMAŃSKI, Lambert van NISTELROOIJ, Maria da Graça CARVALHO

Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.9 – paragraph 1

Clinical trials are the means to transfer biomedical knowledge to application in patients and support for these will be provided, as well as for the improvement of their practice. Examples include the development of better methodologies to allow trials to focus on relevant population groups, including those suffering from other concomitant diseases and/or already undergoing treatment, the determination of comparative effectiveness of interventions and solutions, as well as enhancing the use of databases and electronic health records as data sources for trials and knowledge transfer. Similarly, support for the transfer of other types of interventions such as those related to independent living into real world environments will be provided. Particular importance will be given to clinical tests in the field of rare diseases and child illnesses including those associated with premature birth.

2012/07/05
Committee: ITRE

Peter LIESE, Christian EHLER, Konrad SZYMAŃSKI, Maria da Graça CARVALHO, Markus PIEPER, Werner LANGEN, Herbert REUL

Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.15 a (new)

1.15a. Life sciences for medicine: Priority should be given to research efforts which one Member State alone cannot undertake or cannot undertake as efficiently as the Union and which will directly benefit patients in the foreseeable future.

2012/07/05
Committee: ITRE

7 Amendments of Herbert REUL related to 2011/0402(CNS)

ParlTrack - 2011-2024